Cardiovascular and metabolic risk profile in german patients with moderate and severe psoriasis: A case control study

European Journal of Dermatology

Volumn 21, Issue 5, 2011, Pages 761-770

  Warnecke, Christine ^a   Manousaridis, Ioannis ^a   Herr, Raphael ^b   Terris, Darcey D ^b,c   Goebeler, Matthias ^a,d   Goerdt, Sergij ^a   Peitsch, Wiebke K ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF GEORGIA   (United States)

^d JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Adiponectin; Cholesterol; Inflammation; Insulin resistance; Myocardial infarction; Psoriasis

Indexed keywords

ADIPONECTIN; CHOLESTEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; GERMANY; HEALTH HAZARD; HEART INFARCTION; HOSPITALIZATION; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC RISK; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OBESITY; PREVALENCE; PSORIASIS; SMOKING;

ADIPONECTIN; ADULT; ARTHRITIS, PSORIATIC; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; COMORBIDITY; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; GERMANY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PSORIASIS; RISK ASSESSMENT;

EID: 80054943830     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2011.1467     Document Type: Article

References (58)

1. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-41.
2. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-35.
3. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157: 68-73.
4. Kimball AB, Gladman D, Gelfand JM, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008; 58: 1031-42.
5. Favato G. High incidence of smoking habit in psoriatic patients. Am J Med 2008; 121: e17.
6. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995; 32: 982-6.
7. Herron MD, Hinckley M, Hoffman MS, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005; 141: 1527-34.
8. Bremmer S, Van Voorhees AS, Hsu S, et al. Obesity and psoriasis: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2010; 63: 1058-69.
9. Gisondi P, Del Giglio M, Di Francesco V, et al. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr 2008; 88: 1242-7.
10. Davidovici BB, Sattar N, Jorg PC, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010; 130: 1785-96.
11. Jin Y, Zhang F, Yang S, et al. Combined effects of HLA-Cw6, body mass index and waist-hip ratio on psoriasis vulgaris in Chinese Han population. J Dermatol Sci 2008; 52: 123-9.
12. Brauchli YB, Jick SS, Meier CR. Psoriasis and the risk of incident diabetes mellitus: a population-based study. Br J Dermatol 2008; 159: 1331-7.
13. Ucak S, Ekmekci TR, Basat O, et al. Comparison of various insulin sensitivity indices in psoriatic patients and their relationship with type of psoriasis. J Eur Acad Dermatol Venereol 2006; 20: 517-22.
14. Boehncke S, Thaci D, Beschmann H, et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007; 157: 1249-51.
15. Boehncke WH, Boehncke S, Schön MP. Managing comorbid disease in patients with psoriasis. BMJ 2010; 340: b5666.22.
16. Mehta NN, Azfar RS, Shin DB, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010; 31: 1000-6.
17. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 2008; 159: 895-902.
18. Wakkee M, Herings RM, Nijsten T. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. J Invest Dermatol 2010; 130: 962-7.
19. Nijsten T, Wakkee M. Complexity of the association between psoriasis and comorbidities. J Invest Dermatol 2009; 129: 1601-3.
20. Gelfand JM, Azfar RS, Mehta NN. Psoriasis and cardiovascular risk: strength in numbers. J Invest Dermatol 2010; 130: 919-22.
21. Gerdes S, Mrowietz U. Impact of comorbidities on the management of psoriasis. Curr Probl Dermatol 2009; 38: 21-36.
22. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23(Suppl. 2): 1-70.
23. Nast A, Boehncke WH, Mrowietz U, et al. Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update 2011. AWMF, register no. 013-001. http://www.awmf.org/uploads/tx_szleitlinien/013-001l_S3_Psoriasis_vulgaris_Therapie_01.pdf.
24. Claes C, Kulp W, Greiner W, Graf von der Schulenberg J, Werfel T, eds. Therapie der mittelschweren und schweren Psoriasis. In: Schriftenreihe Health Technology Assessment. Köln: Deutsches Institut für Medizinische Dokumentation und Information (DIMDI); 2006: Vol. 34: 15.
25. Thomas A, Schussler MN, Fischer JE, et al. Employees' sleep duration and body mass index: potential confounders. Prev Med 2009; 48: 467-70.
26. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665-73.
27. Giannessi D, Maltinti M, Del Ry S. Adiponectin circulating levels: a new emerging biomarker of cardiovascular risk. Pharmacol Res 2007; 56: 459-67.
28. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
29. American Diabetes, Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33(Suppl. 1): S62-9.
30. Gerdes S, Zahl VA, Weichenthal M, et al. Smoking and alcohol intake in severely affected patients with psoriasis in Germany. Dermatology 2010; 220: 38-43.
31. Naldi L, Mercuri SR. Smoking and psoriasis: from epidemiology to pathomechanisms. J Invest Dermatol 2009; 129: 2741-3.
32. Calabro P, Golia E, Yeh ET. CRP and the risk of atherosclerotic events. Semin Immunopathol 2009; 31: 79-94.
33. Coimbra S, Oliveira H, Reis F, et al. C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy. J Eur Acad Dermatol Venereol 2010; 24: 789-96.
34. Sergeant A, Makrygeorgou A, Chan WC, et al. C-reactive protein in psoriasis. Br J Dermatol 2008; 158: 417-9.
35. Yiu KH, Yeung CK, Chan HT, et al. Increased arterial stiffness in patients with psoriasis is associated with active systemic inflammation. Br J Dermatol 2010; 164: 514-20.
36. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95.
37. Gottlieb AB, Dann F. Comorbidities in patients with psoriasis. Am J Med 2009; 122: 1150 e1-9.
38. Poole CD, Conway P, Currie CJ. An evaluation of the association between C-reactive protein, the change in C-reactive protein over one year, and all-cause mortality in chronic immune-mediated inflammatory disease managed in UK general practice. Rheumatology (Oxford) 2009; 48: 78-82.
39. Prodanovich S, Ma F, Taylor JR, et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005; 52: 262-7.
40. Mallbris L, Granath F, Hamsten A, et al. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006; 54: 614-21.
41. Akhyani M, Ehsani AH, Robati RM, et al. The lipid profile in psoriasis: a controlled study. J Eur Acad Dermatol Venereol 2007; 21: 1330-2.
42. Tekin NS, Tekin IO, Barut F, et al. Accumulation of oxidized lowdensity lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediators Inflamm 2007; 2007: 78454.
43. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-5.
44. Pietrzak A, Michalak-Stoma A, Chodorowska G, Szepietowski JC. Lipid disturbances in psoriasis: an update. Mediators Inflamm 2010.(Epub ahead of print).
45. Seishima M, Mori S, Noma A. Serum lipid and apolipoprotein levels in patients with psoriasis. Br J Dermatol 1994; 130: 738-42.
46. Uyanik BS, Ari Z, Onur E, et al. Serum lipids and apolipoproteins in patients with psoriasis. Clin Chem Lab Med 2002; 40: 65-8.
47. Reynoso-von Drateln C, Martinez-Abundis E, Balcazar-Munoz BR, et al. Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. J Am Acad Dermatol 2003; 48: 882-5.
48. Love TJ, Qureshi AA, Karlson EW, Gelfand JM, Choi HK. Prevalence of the metabolic syndrome in psoriasis: results from the national health and nutrition examination survey, 2003-2006. Arch Dermatol 2011; 147: 419-24.
49. Takahashi H, Tsuji H, Takahashi I, et al. Plasma adiponectin and leptin levels in Japanese patients with psoriasis. Br J Dermatol 2008; 159: 1207-8.
50. Shibata S, Saeki H, Tada Y, et al. Serum high molecular weight adiponectin levels are decreased in psoriasis patients. J Dermatol Sci 2009; 55: 62-3.
51. Coimbra S, Oliveira H, Reis F, et al. Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy. J Eur Acad Dermatol Venereol 2010; 24: 1386-94.
52. Kaur S, Zilmer K, Kairane C, et al. Clear differences in adiponectin level and glutathione redox status revealed in obese and normal-weight patients with psoriasis. Br J Dermatol 2008; 159: 1364-7.
53. Kaur S, Zilmer K, Leping V, Zilmer M. The levels of adiponectin and leptin and their relation to other markers of cardiovascular risk in patients with psoriasis. J Eur Acad Dermatol Venereol 2011.(Epub ahead of print).
54. Löwel H, Meisinger C, Heier M, Hymer H, Alte D, Völzke H. Epidemiology of hypertension in Germany. Selected results of population-representative cross-sectional studies. Dtsch Med Wochenschr 2006; 131: 2586-91.
55. Prey S, Paul C, Bronsard V, et al. Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies. J Eur Acad Dermatol Venereol 2010; 24(Suppl. 2): 23-30.
56. Tobin AM, Veale DJ, Fitzgerald O, et al. Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis. J Rheumatol 2010; 37: 1386-94.
57. Tam LS, Tomlinson B, Chu TT, et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls - the role of inflammation. Rheumatology (Oxford) 2008; 47: 718-23.
58. Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009; 68: 1131-5.